Cure My Disease

Don't miss your cure!

 Log in / Sign up

Supercharged flu vaccine shows promise for seniors

NCT ID NCT04024228

Completed Prevention Sponsor: Sanofi Pasteur, a Sanofi Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether a high-dose flu vaccine (QIV-HD) works better than the standard-dose vaccine in adults aged 60 and older. Over 1,500 healthy volunteers received either the high-dose or standard shot. Researchers measured immune responses 28 days later to see if the high-dose version triggers stronger protection against four flu strains.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
High-dose quadrivalent influenza vaccine (QIV-HD)
What this could lead to
If successful, this could provide better flu protection for older adults, who are at higher risk of severe illness.
What could go wrong
This is a completed phase 3 trial, but results may show only modest improvement over standard vaccine, and individual responses vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS INFLUENZA IMMUNIZATION

Contacts and locations

Locations

  • Investigational Site Number 0560001

    Ghent, BE-9000, Belgium

  • Investigational Site Number 0560002

    Wilrijk, 2610, Belgium

  • Investigational Site Number 2500001

    Gières, 38610, France

  • Investigational Site Number 2500003

    Pierre-Bénite, 69495, France

  • Investigational Site Number 2500004

    Paris, 75014, France

  • Investigational Site Number 2760001

    Essen, 45136, Germany

  • Investigational Site Number 2760002

    Oldenburg in Holstein, 23758, Germany

  • Investigational Site Number 2760003

    Berlin, 10629, Germany

  • Investigational Site Number 2760004

    Berlin, 13347, Germany

  • Investigational Site Number 2760005

    Berlin, 10787, Germany

  • Investigational Site Number 3800001

    Genova, IT-16132, Italy

  • Investigational Site Number 3800003

    Palermo, 90127, Italy

  • Investigational Site Number 5280001

    Utrecht, 3584 CX, Netherlands

  • Investigational Site Number 6160001

    Dębica, 39-200, Poland

  • Investigational Site Number 6160002

    Wola, 43-225, Poland

  • Investigational Site Number 6160003

    Siemianowice Śląskie, 41-103, Poland

  • Investigational Site Number 6160004

    Wroclaw, 50-452, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.